The use of ANAM to assess the side-effect profiles and efficacy of medication

Abstract

Cognition has become increasingly important as an outcome measure in studies of medication. Traditional neuropsychological assessment is limited in its ability to detect subtle, medication-related changes and it is not suitable for the rapid serial assessment required in most clinical trials. Thus, investigators have turned to computerized neuropsychological assessment for its repeatability, sensitivity to subtle cognitive changes, and ease of administration. The automated neuropsychological assessment metrics (ANAM) is one such computerized battery that has been used to measure the effects of numerous CNS-active drugs. This paper is an exhaustive review of studies that have used ANAM to measure cognitive changes associated with pharmacological treatments. The benefits and limitations of using ANAM in clinical trials are discussed.

Age differences in cognitive and psychomotor abilities and simulated driving

“…The computerized tests were based on those found in other well-established batteries such as the automated neuropsychological assessment metrics (ANAM). ANAM has been shown to be sensitive to cognitive impairments caused by medication side effects (e.g., Wilken et al, 2007) and mild traumatic brain injuries (e.g., Vasterling et al, 2006).…”

Automated Neuropsychological Assessment Metrics: Repeated Assessment with Two Military Samples

“…The asterisk stimulus in SRT and the digits 1-9 in CDS and CDD are not replaced or reordered and so are presented in the same fashion for all administrations of those subtests. These alternate forms of ANAM, generated by the pseudorandomized selection of comparable test items that are then presented in the same test paradigm, are widely reported as equivalent in published research ( 25,30 ).…”

Performance of the Automated Neuropsychological Assessment Metrics (ANAM) in detecting cognitive impairment in heart failure patients

“…The ANAM has already shown a wide range of utility in studies assessing the cognitive effects of concussions, 37,38 environmental stressors and exposures, 39-42 and medications and drugs of abuse. 43,44 It has served as an efficient tool for monitoring cognitive deficits in a range of patients, from screening military personnel for minor traumatic brain injuries and neuropsychological deficits, 45-49 to managing chronic medical conditions, including systemic lupus erythematosus 50,51 and multiple sclerosis. 52 Recently, in a mixed clinical sample, the ANAM significantly predicted CI status with a sensitivity of 81% and specificity of 89.1%.…”